Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-53P is annotated as a pseudogene of the U4 small nuclear RNA (snRNA) family. Pseudogenes are generally regarded as non-functional genomic elements derived from ancestral active genes, frequently carrying mutations that render them nonfunctional. While the functional U4 small nuclear RNAs (such as RNU4-2) are critical components of the major spliceosome and participate in pre-mRNA splicing, RNU4-53P is not known to produce a functional RNA product, does not encode a protein, and has no demonstrated biological or disease association. Consequently, it is not considered a therapeutic target, nor are there known drugs, biomarkers, or safety concerns associated with it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 53, pseudogene (RNU4-53P).